CompletedNot Applicable

Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum

Iraq7,020 participantsStarted 2012-05

Plain-language summary

The use of a new generation low molecular weight heparin (Bemiparin)and the well known LMWH (Enoxaparin) after Caesarean sections and vaginal deliveries in a risky group patients for venous thrombosis.

Who can participate

Age range15 Years – 48 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Presence of risk factors for venous thromboembolism * Any parity * Mode of delivery:vaginal, Emergency and Elective Caesarean section * No any contraindications for Heparin Exclusion Criteria: * Active antenatal or postpartum vaginal bleeding. * Placenta previa * Thrombocytopenia * Sever renal or liver diseases * Uncontrolled sever hypertension * Any patient who is already on Heparin during pregnancy

What they're measuring

Venous thromboembolism

Timeframe: 40 days after delivery

Trial details

NCT IDNCT01588171

SponsorHawler Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-10

View on ClinicalTrials.gov More Venous Thromboembolic Diseases trials